Nasopharyngeal Carcinoma

NCI Definition: A carcinoma arising from the nasopharyngeal epithelium. It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma. [1]

Clinical Trials

View Clinical Trials for Nasopharyngeal Carcinoma

There are 38 clinical trials for nasopharyngeal carcinoma, of which 29 are open and 9 are completed or closed. Of the trials that contain nasopharyngeal carcinoma as an inclusion criterion, 11 are phase 1 (8 open), 8 are phase 1/phase 2 (7 open), 15 are phase 2 (11 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (2 open).

EBV, Epstein-Barr, and EGFR are the most frequent gene inclusion criteria for nasopharyngeal carcinoma clinical trials [3].

Trials Investigating Nasopharyngeal Carcinoma by Gene and Recruiting Status

Nivolumab, cisplatin, and cyclophosphamide are the most common interventions in nasopharyngeal carcinoma clinical trials.

Drugs Being Investigated in Nasopharyngeal Carcinoma Trials by Recruiting Status

Significant Genes in Nasopharyngeal Carcinoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF19 +

FGF19 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF4 +

FGF4 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF4 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Cancer of the Nasopharynx, Nasopharyngeal Throat Cancer, NPC, Cancer of Nasopharynx, Carcinoma of Nasopharynx, Nasopharyngeal carcinoma, nasopharyngeal cancer, Nasopharyngeal Cancer, Carcinoma of the Nasopharynx

Parent(s)

Malignant Nasopharyngeal Neoplasm

Children

Nasopharyngeal Papillary Adenocarcinoma, Nasopharyngeal Salivary Gland-Type Carcinoma, and Nasopharyngeal Squamous Cell Carcinoma

OncoTree Name

Nasopharyngeal Carcinoma

OncoTree Code

NPC

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Nasopharyngeal Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Nasopharyngeal Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types